Targeting BRCA-mutated tumors in mitosis

被引：0

作者：

Demis Menolfi

Shan Zha

机构：

[1] Columbia University,Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons

[2] Columbia University,Division of Pediatric Oncology, Hematology and Stem Cell Transplantation, Department of Pediatrics, Vagelos College of Physicians and Surgeons

来源：

Nature Cancer | 2021年 / 2卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A genome-wide CRISPR screen finds CIP2A as a new synthetic lethal target for BRCA1- and BRCA2-deficient cells. Unlike PARP inhibition that increases replication-induced DNA double-strand breaks and radial chromosomes, depleting CIP2A or disrupting its interaction with TOPBP1 increases micronuclei and chromosomal missegregation, revealing a mitotic target for BRCA-mutated tumors.

引用

页码：1296 / 1297

页数：1

共 50 条

[41] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
Le, Dan
Gelmon, Karen A.
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
[42] Could sensitivity to DDP of BRCA-mutated ovarian cancers be a predictor of longer survival?
Artioli, Grazia
Nicoletto, M. Ornella
D'Andrea, Emma
Palma, Maurizia Dalla
Nardelli, Gianni
Mocellin, Simone
Falci, Cristina
Ambrosini, Antonio
Monfardini, Silvio
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 133 - 133
[43] Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer
Oh, Do-Youn
Park, Joon Oh
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Arnold, Dirk
Reinacker-Schick, Anke
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen M.
McGuiness, David
Liu, Yu-Zhen
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
[44] DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
Aleskandarany, Mohammed
Caracappa, Daniela
Nolan, Christopher C.
Macmillan, R. Douglas
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 81 - 90
[45] DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
Mohammed Aleskandarany
Daniela Caracappa
Christopher C. Nolan
R. Douglas Macmillan
Ian O. Ellis
Emad A. Rakha
Andrew R. Green
[J]. Breast Cancer Research and Treatment, 2015, 150 : 81 - 90
[46] Targeting c-met and DNA double-strand break (DSB) repair pathways for BRCA-mutated gastric carcinomas
Karamouzis, M. V.
Mihailidou, C.
Papakotoulas, P.
Anestis, A.
Koustas, E.
Papavassiliou, A. G.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[47] Perceptions about benefits and risks associated with estroprogestins contraceptive in BRCA-mutated women
Barra, Fabio
Monari, Francesca
Sola, Valentina Boggio
Cortesi, Laura
Toss, Angela
del Savio, Chiara
Melotti, Chiara
Centurioni, Maria Grazia
Gustavino, Claudio
Varesco, Liliana
Facchinetti, Fabio
Grandi, Giovanni
[J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 200 - 201
[48] Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
Arjun Mittra
Geraldine H. O’ Sullivan Coyne
Jennifer Zlott
Shivaani Kummar
Robert Meehan
Lawrence Rubinstein
Lamin Juwara
Deborah Wilsker
Jiuping Ji
Brandon Miller
Tony Navas
Katherine V. Ferry-Galow
Andrea Regier Voth
Ting-Chia Chang
Shahanawaz Jiwani
Ralph E. Parchment
James H. Doroshow
Alice P. Chen
[J]. Cancer Chemotherapy and Pharmacology, 2024, 93 : 177 - 189
[49] Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients
Rocco, Nicola
Montagna, Giacomo
Criscitiello, Carmen
Nava, Maurizio Bruno
Privitera, Francesca
Taher, Wafa
Gloria, Antonio
Catanuto, Giuseppe
[J]. GENES, 2021, 12 (02) : 1 - 7
[50] Targeting one-carbon metabolism in syngeneic mouse model of BRCA-mutated high-grade serous ovarian cancer
Rubinsak, L. A.
Wallace-Povirk, A.
Hou, Z.
O'Connor, C.
Gangjee, A.
Morris, R. T.
Matherly, L.
[J]. GYNECOLOGIC ONCOLOGY, 2020, 159 : 101 - 101

← 1 2 3 4 5 →